Analyst Daniel Brennan of TD Cowen maintained a Buy rating on Pacific Biosciences (PACB – Research Report), with a price target of $3.50.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Daniel Brennan has given his Buy rating due to a combination of factors impacting Pacific Biosciences. Despite a reduction in revenue expectations for 2025, the company has taken a more realistic approach by accounting for potential risks such as NIH funding pressures and broader macroeconomic challenges. This conservative guidance offers a more grounded outlook after missing targets in previous quarters.
Moreover, Pacific Biosciences is making significant strides in cost management by reducing its cost of goods sold and operating expenses, which aligns with their strategy to achieve positive free cash flow by the end of 2027. The company is also expanding its technological offerings with new platform launches, which could strengthen its market position in emerging areas like clinical applications and population sequencing programs. While the stock is not considered ‘cheap’ from a valuation standpoint, the long-term growth potential remains attractive due to these strategic initiatives and reduced financial burn.